GENinCode (LON:GENI) Stock Price Down 8.6% – Here’s Why

Shares of GENinCode Plc (LON:GENI) were down 8.6% during trading on Friday . The company traded as low as GBX 0.80 and last traded at GBX 0.80. Approximately 3,159,584 shares were traded during trading, a decline of 45% from the average session volume of 5,785,926 shares. The stock had previously closed at GBX 0.88.

GENinCode Stock Performance

The stock has a market cap of £6.02 million, a price-to-earnings ratio of -0.38 and a beta of 0.59. The firm’s 50-day moving average is GBX 0.95 and its two-hundred day moving average is GBX 1.15. The company has a current ratio of 0.93, a quick ratio of 15.88 and a debt-to-equity ratio of 117.74.

GENinCode (LON:GENI) last posted its quarterly earnings data on Monday, June 8th. The company reported GBX (2.08) earnings per share (EPS) for the quarter. GENinCode had a negative return on equity of 409.40% and a negative net margin of 185.47%.The firm had revenue of GBX 308 million during the quarter. As a group, sell-side analysts expect that GENinCode Plc will post -7.1299999 earnings per share for the current year.

GENinCode Company Profile

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.